Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: LNG099
MIFTS: 70

Lung Disease

Categories: Blood diseases, Respiratory diseases
Genes Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Lung Disease

About this section

MalaCards integrated aliases for Lung Disease:

Name: Lung Disease 12 15 17
Lung Diseases 56 44 45 74
Disorder of Lung 30

Classifications:

MalaCards categories:
Anatomical: Respiratory diseases Blood diseases
See all MalaCards categories (disease lists)
ICD10: 34


External Ids:

Disease Ontology 12 DOID:850
MeSH 45 D008171
NCIt 51 C3198
SNOMED-CT 69 19829001
ICD10 34 J60-J70 J98.4
UMLS 74 C0024115
Sources

Summaries for Lung Disease

About this section
MedlinePlus : 44 When you breathe, your lungs take in oxygen from the air and deliver it to the bloodstream. The cells in your body need oxygen to work and grow. During a normal day, you breathe nearly 25,000 times. People with lung disease have difficulty breathing. Millions of people in the U.S. have lung disease. If all types of lung disease are lumped together, it is the number three killer in the United States. The term lung disease refers to many disorders affecting the lungs, such as asthma, COPD, infections like influenza, pneumonia and tuberculosis, lung cancer, and many other breathing problems. Some lung diseases can lead to respiratory failure. Dept. of Health and Human Services Office on Women's Health

MalaCards based summary : Lung Disease, also known as lung diseases, is related to interstitial lung disease and pulmonary disease, chronic obstructive, and has symptoms including dyspnea, apnea and hemoptysis. An important gene associated with Lung Disease is SFTPC (Surfactant Protein C), and among its related pathways/superpathways are Metabolism of proteins and Akt Signaling. The drugs Pirfenidone and Beractant have been mentioned in the context of this disorder. Affiliated tissues include lung, testes and heart, and related phenotypes are homeostasis/metabolism and growth/size/body region

Disease Ontology : 12 A lower respiratory tract disease in which the function of the lungs is adversely affected by narrowing or blockage of the airways resulting in poor air flow, a loss of elasticity in the lungs that produces a decrease in the total volume of air that the lungs are able to hold, and clotting, scarring, or inflammation of the blood vessels that affect the ability of the lungs to take up oxygen and to release carbon dioxide.

Sources

Related Diseases for Lung Disease

About this section

Diseases related to Lung Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 676)
# Related Disease Score Top Affiliating Genes
1 interstitial lung disease 34.4 ABCA3 CXCL8 IFIH1 IL10 IL1B ITGA3
2 pulmonary disease, chronic obstructive 33.4 CFTR CXCL8 ELANE SERPINA1 SFTPB SFTPD
3 desquamative interstitial pneumonia 33.1 ABCA3 MUC5B SFTPC
4 pneumoconiosis 33.0 CXCL8 IL1B MUC5B SERPINA1 TNF
5 alpha-1-antitrypsin deficiency 32.9 CXCL8 ELANE SERPINA1
6 cystic fibrosis 32.9 CFTR CXCL8 ELANE SERPINA1 SFTPD
7 extrinsic allergic alveolitis 32.9 CXCL8 IL10 IL1B SFTPD
8 surfactant dysfunction 32.9 ABCA3 SFTPA1 SFTPB SFTPC
9 silicosis 32.8 CXCL8 IL1B SFTPD TNF
10 pulmonary fibrosis 32.7 IL1B MUC5B SFTPA1 SFTPA2 SFTPC SFTPD
11 bronchopulmonary dysplasia 32.7 CXCL8 ELANE SFTPB
12 bagassosis 32.7 CXCL8 IL1B
13 aspergillosis 32.7 CFTR ELANE IL10 SFTPA2 SFTPD TNF
14 respiratory failure 32.6 CXCL8 ELANE SERPINA1 SFTPB SFTPC SFTPD
15 bronchiolitis 32.5 CXCL8 IL10 MUC5B TNF
16 asthma 32.5 CFTR CXCL8 ELANE IL10 IL1B TNF
17 pulmonary fibrosis, idiopathic 32.5 ABCA3 CXCL8 ELANE IL1B MUC5B SFTPA1
18 allergic bronchopulmonary aspergillosis 32.5 CFTR SFTPA2 SFTPD
19 pulmonary alveolar proteinosis 32.5 SFTPB SFTPC SFTPD
20 respiratory distress syndrome in premature infants 32.5 ABCA3 SFTPA1 SFTPB SFTPC
21 bronchiolitis obliterans 32.4 CXCL8 IL10 TNF
22 idiopathic interstitial pneumonia 32.3 CXCL8 ELANE MUC5B SFTPA1 SFTPA2 SFTPC
23 pneumonia 32.3 CXCL8 ELANE IL10 IL1B MUC5B SFTPB
24 arthritis 31.6 CXCL8 IL10 IL1B TNF
25 bronchiectasis 31.3 CFTR CXCL8 ELANE SERPINA1
26 mycobacterium abscessus 31.2 CFTR CXCL8 SERPINA1 TNF
27 bronchitis 31.0 CFTR CXCL8 ELANE SERPINA1 TNF
28 colitis 30.8 CXCL8 IL10 IL1B TNF
29 sleep apnea 30.8 CXCL8 IL1B TNF
30 haemophilus influenzae 30.7 CXCL8 IL1B TNF
31 ulcerative colitis 30.7 CXCL8 IL10 IL1B TNF
32 acute respiratory distress syndrome 30.6 CXCL8 ELANE IL1B SFTPB SFTPC SFTPD
33 chorioamnionitis 30.6 CXCL8 ELANE IL1B TNF
34 pulmonary emphysema 30.4 ELANE SERPINA1 SFTPC SFTPD
35 vasculitis 30.4 ELANE SERPINA1 TNF
36 acquired immunodeficiency syndrome 30.4 IL10 IL1B TNF
37 bacterial pneumonia 30.3 CXCL8 ELANE SFTPB SFTPD
38 pulmonary edema 30.2 CFTR CXCL8 IL10 IL1B TNF
39 rheumatic disease 30.2 IL10 IL1B TNF
40 chronic mucocutaneous candidiasis 30.2 IL10 IL1B TNF
41 cytomegalovirus infection 30.2 CXCL8 IL1B TNF
42 neonatal respiratory failure 30.2 ABCA3 SFTPB SFTPC
43 adult respiratory distress syndrome 30.2 CXCL8 ELANE IL10 SFTPB SFTPC TNF
44 inflammatory bowel disease 30.1 CXCL8 IL10 IL1B TNF
45 clonorchiasis 30.1 CXCL8 IL10 TNF
46 funisitis 30.1 CXCL8 IL10 IL1B
47 crohn's colitis 30.1 CXCL8 IL1B TNF
48 bacterial vaginosis 30.0 CXCL8 IL1B TNF
49 pertussis 30.0 IL10 IL1B TNF
50 contact dermatitis 30.0 CXCL8 IL10 IL1B TNF

Graphical network of the top 20 diseases related to Lung Disease:



Diseases related to Lung Disease
Sources

Symptoms & Phenotypes for Lung Disease

About this section

UMLS symptoms related to Lung Disease:


dyspnea, apnea, hemoptysis, snoring, coughing, labored breathing

MGI Mouse Phenotypes related to Lung Disease:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.2 ABCA3 CFTR ELANE IFIH1 IL10 IL1B
2 growth/size/body region MP:0005378 10.18 CFTR IFIH1 IL10 IL1B ITGA3 MUC5B
3 hematopoietic system MP:0005397 10.11 CFTR ELANE IFIH1 IL10 IL1B MUC5B
4 mortality/aging MP:0010768 10.06 ABCA3 CFTR ELANE IFIH1 IL10 IL1B
5 immune system MP:0005387 10.03 CFTR ELANE IFIH1 IL10 IL1B ITGA3
6 neoplasm MP:0002006 9.61 ELANE IL10 IL1B ITGA3 SFTPC TERT
7 respiratory system MP:0005388 9.4 ABCA3 CFTR IL10 ITGA3 MUC5B SFTPA1
Sources

Drugs & Therapeutics for Lung Disease

About this section

Drugs for Lung Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 1315)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Pirfenidone Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 53179-13-8 40632
2 Beractant Approved Phase 4,Phase 2,Not Applicable 108778-82-1
3
Budesonide Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 51333-22-3 5281004 63006
4
Bosentan Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 147536-97-8 104865
5
Sodium Citrate Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 68-04-2
6
Azithromycin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 83905-01-5 447043 55185
7
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 22916-47-8 4189
8
Caspofungin Approved Phase 4,Phase 2,Phase 1,Not Applicable 162808-62-0, 179463-17-3 2826718 468682
9
Fluticasone Approved, Experimental Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 90566-53-3 62924
10
Iloprost Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 78919-13-8 6443959
11
Terbutaline Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 23031-25-6 5403
12
Prednisone Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 53-03-2 5865
13
Metoprolol Approved, Investigational Phase 4,Phase 3,Not Applicable 37350-58-6, 51384-51-1 4171
14
tannic acid Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 1401-55-4
15
Benzocaine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 1994-09-7, 94-09-7 2337
16
Nitric Oxide Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 10102-43-9 145068
17
Iron Approved, Experimental Phase 4,Phase 3,Phase 2,Not Applicable 7439-89-6, 15438-31-0 27284 23925
18
Doxycycline Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 564-25-0 54671203
19
Simvastatin Approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 79902-63-9 54454
20
Mannitol Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 69-65-8 6251 453
21
Prednisolone Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 50-24-8 5755
22
Sulbactam Approved Phase 4,Phase 3,Phase 1,Phase 2 68373-14-8
23
Ampicillin Approved, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 69-53-4 6249
24
Sultamicillin Approved, Investigational Phase 4,Phase 3 76497-13-7
25
Prednisolone phosphate Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 302-25-0
26
Methylprednisolone hemisuccinate Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 2921-57-5
27
Methylprednisolone Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 83-43-2 6741
28
Ipratropium Approved, Experimental Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 22254-24-6, 60205-81-4 657309 43232
29
Epinephrine Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 51-43-4 5816
30
Racepinephrine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 329-65-7 838
31
Isoniazid Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 54-85-3 3767
32
Rifampicin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 13292-46-1 5381226 5458213
33
Pyrazinamide Approved, Investigational Phase 4,Phase 3,Phase 2 98-96-4 1046
34
Metformin Approved Phase 4,Phase 2,Early Phase 1 657-24-9 14219 4091
35
Tadalafil Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 171596-29-5 110635
36
Epoprostenol Approved Phase 4,Phase 3,Phase 2 35121-78-9, 61849-14-7 5282411 5280427
37
Dalteparin Approved Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1 9005-49-6
38
Heparin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 9005-49-6 46507594 772
39
Enoxaparin Approved Phase 4,Phase 3,Phase 2,Not Applicable 9005-49-6 772
40
Riluzole Approved, Investigational Phase 4 1744-22-5 5070
41
Dexmedetomidine Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 113775-47-6 5311068 68602
42
Midazolam Approved, Illicit Phase 4,Phase 3,Phase 1,Not Applicable 59467-70-8 4192
43
Remifentanil Approved Phase 4,Not Applicable 132875-61-7 60815
44
Clarithromycin Approved Phase 4,Phase 3,Phase 2 81103-11-9 84029
45
Ciprofloxacin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 85721-33-1 2764
46
Piperacillin Approved Phase 4,Phase 3,Not Applicable 66258-76-2 43672
47
Cefuroxime Approved Phase 4,Phase 2,Phase 3,Not Applicable 55268-75-2 5479529 5361202
48
Penicillin G Approved, Vet_approved Phase 4,Phase 3 61-33-6 5904
49
Moxifloxacin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 354812-41-2, 151096-09-2 152946
50
Tazobactam Approved Phase 4,Phase 3,Phase 1,Not Applicable 89786-04-9 123630

Interventional clinical trials:

(show top 50) (show all 10000)
# Name Status NCT ID Phase Drugs
1 Pirfenidone in Progressive Interstitial Lung Disease Associated With Clinically Amyopathic Dermatomyositis Unknown status NCT02821689 Phase 4 Pirfenidone
2 Prevention of Chronic Lung Disease (CLD) in Preterm Infants Unknown status NCT00883532 Phase 4 budesonide;surfactant and air (placebo)
3 Comparison of Efficacy Different Treatment Regimens in Pulmonary Hypertension Secondary to Lung Disease and or Hypoxia Unknown status NCT01449253 Phase 4 Sildenafil;Bosentan
4 Prophylactic Antibiotic Treatment of Patients With Chronic Obstructive Lung Disease (COLD) Unknown status NCT00132860 Phase 4 azithromycin
5 Bosentan in Pulmonary Hypertension in Interstitial Lung Disease Treatment Study Unknown status NCT00637065 Phase 4 Bosentan;Placebo
6 Efficacy and Safety of Caspofungin for Invasive Pulmonary Aspergillosis Underlying Chronic Obstructive Pulmonary Disease Unknown status NCT01499433 Phase 4 caspofungin
7 Inhaler Lung Deposition in Chronic Obstructive Pulmonary Disease (COPD) Unknown status NCT01721291 Phase 4 SALBUTAMOL
8 Seasonal Influenza Vaccine, Quadrivalent Versus Trivalent in Patients With Advanced Chronic Obstructive Pulmonary Disease Unknown status NCT02563184 Phase 4
9 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effect of Roflumilast on Endothelial Function in Patients With Chronic Obstructive Pulmonary Disease Unknown status NCT01595750 Phase 4 Roflumilast 500;Placebo
10 Effects of Exercise Training on Systemic Inflammation an Muscle Repair According to the Obstructive Chronic Pulmonary Disease (COPD) Phenotype Unknown status NCT01431625 Phase 4
11 Comparing Treatment Efficacy With HD/MD Flu Plus Sal in Chronic Obstructive Pulmonary Disease (COPD) Patients Unknown status NCT01131806 Phase 4 fluticasone/ salmeterol 125/25 mcg/puff;fluticasone/ salmeterol 250/25 mcg/puff
12 Inhaled Iloprost for Disproportionate Pulmonary Hypertension in Chronic Obstructive Pulmonary Disease (COPD) Unknown status NCT01116063 Phase 4 Inhaled iloprost
13 Efficacy and Safety of Tulobuterol Patch Combined With Tiotropium Bromide for Relieving Dyspnea Symptom of Chronic Obstructive Pulmonary Disease Unknown status NCT01465906 Phase 4 tulobuterol;Tiotropium Bromide;tiotropium bromide
14 The Role of Opinion Leaders in Enhancing Evidence-based Care After Chronic Obstructive Pulmonary Disease (COPD) Emergency Department (ED) Visits Unknown status NCT01107613 Phase 4
15 Metoprolol and Formoterol in Chronic Obstructive Pulmonary Disease (COPD) Unknown status NCT00288548 Phase 4 Metoprolol
16 Can Advair and Flovent Reduce Systemic Inflammation Related to Chronic Obstructive Pulmonary Disease (COPD)? A Multi-Center Randomized Controlled Trial Unknown status NCT00120978 Phase 4 Advair;Flovent
17 Exacerbation Prevention GOLD IV COPD With Non Invasive Mechanical Ventilation Unknown status NCT01481727 Phase 4
18 Inspiratory Muscle Training for Breathless Patients With Chronic Obstructive Pulmonary Disease and Heart Failure Unknown status NCT02579200 Phase 4
19 Evaluate the Efficacy of Xuebijing Injection in Acute Exacerbations of COPD Unknown status NCT02937974 Phase 4 Xuebijing;Placebo
20 Small Airways Evaluation and Treatment Unknown status NCT02526758 Phase 4 beclomethasone;formoterol;budesonide
21 Exhaled NO Based Treatment of Chronic Obstructive Pulmonary Disease (COPD), ICS/LABA Versus LAMA Unknown status NCT02546349 Phase 4 fluticasone/salmeterol, tiotropium
22 Pulmonary Gas Exchange Response to Indacaterol in COPD Unknown status NCT02547558 Phase 4 Indacaterol
23 Effect of Intravenous Iron (Ferinject®) on Exercise Capacity and Quality of Life of Stable COPD Patients Unknown status NCT02416778 Phase 4 Ferric carboxymaltose, Ferinject® 50mg Iron/ml Solution for Injection / Infusion
24 Doxycycline and Airway Inflammation in Chronic Obstructive Pulmonary Disease (COPD) Unknown status NCT00857038 Phase 4 Doxycycline;Placebo
25 Simvastatin in Chronic Obstructive Pulmonary Disease (COPD) Unknown status NCT00680641 Phase 4 Simvastatin;Placebo
26 Predictor for an Additional Benefit of Inhaled Corticosteroid in Patients Treated With Tiotropium for COPD Unknown status NCT00860938 Phase 4 Budesonide
27 Multicenter Trial for the Evaluation of a Fixed Dose Combined Tablet for the Treatment of Pulmonary Tuberculosis Unknown status NCT00216333 Phase 4 combined fixed dose combination
28 Acute Effect of Sildenafil on Exercise Tolerance and Functional Capacity in COPD, IPF and Post Pneumonectomy Patients Unknown status NCT01382368 Phase 4 Sildenafil
29 Study to Demonstrate That Antibiotics Are Not Needed in Moderate Acute Exacerbations of COPD Unknown status NCT01892488 Phase 4 Sultamicillin;Placebo
30 LTOT in COPD Patients With Moderate Chronic Hypoxemia and Chronic Heart Failure Unknown status NCT00668408 Phase 4
31 The Efficacy and Safety of Salmeterol/Fluticasone Propionate vs Atropium/Albuterol in Patients COPD Unknown status NCT01243788 Phase 4 Salmeterol/Fluticasone Propionate
32 Description of the Ability to Learn How to Handle Inhaler Devices in COPD Unknown status NCT02813200 Phase 4 Seretide® Diskus® 500/550 μg;Ultibro® Breezhaler® 110/50 μg;Spiriva® Respimat® 2,5 μg
33 Effects of Nutritional Supplementation in Malnourished Patients in Stable COPD Unknown status NCT02197871 Phase 4
34 Airway Effects of Tiotropium in Patients With COPD Unknown status NCT02683668 Phase 4
35 AeriSeal System in Patients With Advanced Upper Lobe Predominant Emphysema and Collateral Ventilation Unknown status NCT01460108 Phase 4
36 Prednisone Administration in Quiescent COPD Patients to Determine the Effect on Gene Expression Unknown status NCT02534402 Phase 4 Prednisone
37 An Efficacy Study of BCS Clearing the Oral Colonized Bacterium in Hospitalized Patients With COPD Unknown status NCT02269800 Phase 4 Benzalkonium chloride solution;Normal saline
38 Strategy to Improve Adherence of Roflumilast Unknown status NCT02018432 Phase 4 Roflumilast escalation dosage;Roflumilast conventional dosage
39 EUROPT Clinical Trial to Study the Efficacy of One-Way Valve Implantation (New Treatment Algorithm) in Patients With Heterogeneous Emphysema Unknown status NCT00730301 Phase 4
40 Sunovion Brovana Versus Serevent Inspiratory Capacity High Resolution Computed Tomography Unknown status NCT01361984 Phase 4 Nebulized arformoterol;Salmeterol
41 Immunodeficiency in Cartilage-hair Hypoplasia: Sub-project on Safety of Vaccination Against Chickenpox Unknown status NCT02383797 Phase 4
42 Bronchiolitis All-study, SE-Norway Unknown status NCT00817466 Phase 4 Racemic adrenaline;Isotonic saline
43 Reintroduction Regimens After Hepatitis During Anti-tuberculosis Treatment Unknown status NCT01395654 Phase 4 isoniazid, rifampin, pyrazinamide
44 Metformin for Weight Control in Adolescents Taking Atypical Antipsychotics Unknown status NCT00845936 Phase 4 Metformin
45 Long Acting Phosphodiesterase 5 Inhibitors as Add-on Therapy for Patients With Pulmonary Hypertension Treated With Prostanoids. Unknown status NCT00705588 Phase 4 Tadalafil;Vardenafil
46 Comparison of Low-Molecular-Weight Heparin (LMWH) and Unfractionated Heparin (UFH) in Combination With Thrombolytic Treatment of Acute Massive Pulmonary Thromboembolism Unknown status NCT01956955 Phase 4 enoxaparin ,alteplase, unfractionated heparin
47 Non-Invasive Ventilation in Amyotrophic Lateral Sclerosis Unknown status NCT00560287 Phase 4
48 Transfusion Strategies in Weaning Patients Unknown status NCT01256645 Phase 4
49 Safety Evaluation of Dexmedetomidine for EBUS-TBNA Unknown status NCT01381627 Phase 4 Remifentanil;Dexmedetomidine
50 Evaluation and Reconditioning of Marginal Lung Donors to Transplantation by ex Vivo Lung Perfusion Unknown status NCT01353105 Phase 4

Search NIH Clinical Center for Lung Disease

Cochrane evidence based reviews: lung diseases

Sources

Genetic Tests for Lung Disease

About this section

Genetic tests related to Lung Disease:

# Genetic test Affiliating Genes
1 Disorder of Lung 30
Sources

Anatomical Context for Lung Disease

About this section

MalaCards organs/tissues related to Lung Disease:

42
Lung, Testes, Heart, Bone, Neutrophil, Endothelial, Liver
Sources

Publications for Lung Disease

About this section

Articles related to Lung Disease:

(show top 50) (show all 7610)
# Title Authors Year
1
A Rare Case of Adenosquamous Carcinoma Arising in a Background of IgG4-Related Lung Disease: A case report. ( 30853707 )
2019
2
Adult-onset Still's disease-associated interstitial lung disease represents severe phenotype of the disease with higher rate of haemophagocytic syndrome and relapse. ( 30767871 )
2019
3
Caveolae, caveolin-1 and lung diseases of aging. ( 30686114 )
2019
4
Clinical characteristics and outcome in patients with antisynthetase syndrome associated interstitial lung disease: a retrospective cohort study. ( 30834073 )
2019
5
Is incident rheumatoid arthritis interstitial lung disease associated with methotrexate treatment? Results from a multivariate analysis in the ERAS and ERAN inception cohorts. ( 31061059 )
2019
6
Combined Collagen-Induced Arthritis and Organic Dust-Induced Airway Inflammation to Model Inflammatory Lung Disease in Rheumatoid Arthritis. ( 30995344 )
2019
7
Rheumatoid arthritis disease activity predicting incident clinically-apparent RA-associated interstitial lung disease: A prospective cohort study. ( 30951251 )
2019
8
Rituximab Therapy in Interstitial Lung Disease associated with Rheumatoid Arthritis. ( 30963656 )
2019
9
Systemic treatment with resveratrol alleviates adjuvant arthritis-interstitial lung disease in rats via modulation of JAK/STAT/RANKL signaling pathway. ( 30930172 )
2019
10
Malondialdehyde-Acetaldehyde Adducts and Antibody Responses in Rheumatoid Arthritis-Interstitial Lung Disease. ( 30933423 )
2019
11
Rheumatoid Arthritis associated Interstitial Lung Disease (RA-ILD). ( 30937453 )
2019
12
Effect of Biological Disease-modifying Anti-rheumatic Drugs on Airway and Interstitial Lung Disease in Patients with Rheumatoid Arthritis. ( 30799358 )
2019
13
Rheumatoid Arthritis-Interstitial Lung Disease in the United States: Prevalence, Incidence, and Healthcare Costs and Mortality. ( 30710005 )
2019
14
Reinterpreting Evidence of Rheumatoid Arthritis-Associated Interstitial Lung Disease to Understand Etiology. ( 30652645 )
2019
15
Profibrotic effect of IL-17A and elevated IL-17RA in idiopathic pulmonary fibrosis and rheumatoid arthritis-associated lung disease support a direct role for IL-17A/IL-17RA in human fibrotic interstitial lung disease. ( 30604628 )
2019
16
High levels of antibodies to citrullinated α-enolase peptide-1 (CEP-1) identify erosions and interstitial lung disease (ILD) in a Chinese rheumatoid arthritis cohort. ( 30611755 )
2019
17
Risk factors for progression and prognosis of rheumatoid arthritis-associated interstitial lung disease: single center study with a large sample of Chinese population. ( 30535993 )
2019
18
Predicting outcomes in rheumatoid arthritis related interstitial lung disease. ( 30487199 )
2019
19
Rheumatoid Arthritis-Interstitial Lung Disease in the United States: Prevalence, Incidence, and Healthcare Costs and Mortality. ( 30442831 )
2019
20
Interleukin-18 is associated with the presence of interstitial lung disease in rheumatoid arthritis: a cross-sectional study. ( 30269670 )
2019
21
Insights into animal models for cell-based therapies in translational studies of lung diseases: Is the horse with naturally occurring asthma the right choice? ( 30929991 )
2019
22
Isolated Cystic Lung Disease: An Algorithmic Approach to Distinguishing Birt-Hogg-Dubé Syndrome, Lymphangioleiomyomatosis, and Lymphocytic Interstitial Pneumonia. ( 30888864 )
2019
23
Evaluation of bone disease in patients with cystic fibrosis and end-stage lung disease. ( 30843951 )
2019
24
Bronchopulmonary Dysplasia: a Continuum of Lung Disease from the Fetus to the Adult. ( 31091958 )
2019
25
Severe Restrictive Lung Disease in One of the Oldest Documented Males With Coffin-Lowry Syndrome. ( 30791716 )
2019
26
Efficacy of rituximab as a single-agent therapy for the treatment of granulomatous and lymphocytic interstitial lung disease in patients with common variable immunodeficiency. ( 30408616 )
2019
27
BAFF-driven B cell hyperplasia underlies lung disease in common variable immunodeficiency. ( 30843876 )
2019
28
Treatment-Responsive Granulomatous-Lymphocytic Interstitial Lung Disease in a Pediatric Case of Common Variable Immunodeficiency. ( 30984724 )
2019
29
Proceedings of the American College of Rheumatology/Association of Physicians of Great Britain and Ireland Connective Tissue Disease-Associated Interstitial Lung Disease Summit: A Multidisciplinary Approach to Address Challenges and Opportunities. ( 30604506 )
2019
30
Proceedings of the American College of Rheumatology/Association of Physicians of Great Britain and Ireland Connective Tissue Disease-Associated Interstitial Lung Disease Summit: A Multidisciplinary Approach to Address Challenges and Opportunities. ( 30605544 )
2019
31
Approach to the Patient With Connective Tissue Disease and Diffuse Lung Disease. ( 30684993 )
2019
32
Feasibility of low-dose CT with spectral shaping and third-generation iterative reconstruction in evaluating interstitial lung diseases associated with connective tissue disease: an intra-individual comparison study. ( 30737567 )
2019
33
Serum KL-6 levels reflect the severity of interstitial lung disease associated with connective tissue disease. ( 30764869 )
2019
34
Connective Tissue Disease Associated Interstitial Lung Disease - An Acute Exacerbation In Emergency Room. ( 30868797 )
2019
35
Performance of the COPD Assessment Test in patients with connective tissue disease-associated interstitial lung disease. ( 30961943 )
2019
36
A simplified lung ultrasound for the diagnosis of interstitial lung disease in connective tissue disease: a meta-analysis. ( 30975190 )
2019
37
Rituximab in connective tissue disease-associated interstitial lung disease. ( 31016581 )
2019
38
Cellular senescence and senescence-associated secretory phenotype: comparison of idiopathic pulmonary fibrosis, connective tissue disease-associated interstitial lung disease, and chronic obstructive pulmonary disease. ( 31019774 )
2019
39
Pulmonary Manifestations and Progression of Lung Disease in Juvenile-onset Mixed Connective Tissue Disease. ( 30068767 )
2019
40
Imaging and serum biomarkers in connective tissue disease-associated interstitial lung diseases: correlation between lung ultrasound B-lines and KL-6 levels. ( 30352891 )
2019
41
Mysterious quad of constrictive pericarditis, recurrent pleural effusions, bone involvement and interstitial lung disease. ( 30949353 )
2019
42
Oxidative stress and abnormal bioactive lipids in early cystic fibrosis lung disease. ( 31031161 )
2019
43
Lentiviral Vectors for the Treatment and Prevention of Cystic Fibrosis Lung Disease. ( 30875857 )
2019
44
Posaconazole therapy in children with cystic fibrosis and Aspergillus-related lung disease. ( 30877757 )
2019
45
Mycobacterium bolletii Lung Disease in Cystic Fibrosis. ( 30935892 )
2019
46
Single-breath washout and association with structural lung disease in children with cystic fibrosis. ( 30758143 )
2019
47
Adapting Proteostasis and Autophagy for Controlling the Pathogenesis of Cystic Fibrosis Lung Disease. ( 30774592 )
2019
48
Progression of Cystic Fibrosis Lung Disease from Childhood to Adulthood: Neutrophils, Neutrophil Extracellular Trap (NET) Formation, and NET Degradation. ( 30813645 )
2019
49
Quantitative multivolume proton-MRI in patients with cystic fibrosis lung disease: comparison with clinical indicators. ( 30819810 )
2019
50
Targeting of Cathepsin S Reduces Cystic Fibrosis-like Lung Disease. ( 30655278 )
2019
Sources

Variations for Lung Disease

About this section
Sources

Expression for Lung Disease

About this section
Search GEO for disease gene expression data for Lung Disease.
Sources

Pathways for Lung Disease

About this section

Pathways related to Lung Disease according to GeneCards Suite gene sharing:

(show all 34)
# Super pathways Score Top Affiliating Genes
1
Metabolism of proteins 67
Show member pathways
 13.68 ABCA3 CFTR CXCL8 IFIH1 MUC5B NSMCE3
2
Akt Signaling 65
Show member pathways
 13.35 CXCL8 IL10 IL1B ITGA3 TNF TSC1
3
Toll-like Receptor Signaling Pathway 1 38
Show member pathways
 13.02 CXCL8 IL10 IL1B SFTPA2 SFTPD TNF
4
Human cytomegalovirus infection 38
Show member pathways
 12.89 CXCL8 IFIH1 IL1B TNF TSC1 TSC2
5
IL-17 Family Signaling Pathways 66
Show member pathways
 12.24 CFTR CXCL8 IL1B MUC5B TNF
6
Immune response IFN alpha/beta signaling pathway 23
Show member pathways
 12.19 CXCL8 IL10 IL1B TERT TNF
7
IL-1 Family Signaling Pathways 66
Show member pathways
 12.14 CFTR CXCL8 IL1B MUC5B TNF
8
Sudden Infant Death Syndrome (SIDS) Susceptibility Pathways 1
12.1 CXCL8 IL10 IL1B TNF
9
Bacterial infections in CF airways 23
Show member pathways
 12.02 CFTR CXCL8 IL1B SFTPA1 SFTPD TNF
10
Interleukin-4 and 13 signaling 67
11.91 CXCL8 IL10 IL1B TNF
11
AGE-RAGE signaling pathway in diabetic complications 38
11.84 CXCL8 IL1B TNF
12
NF-kappa B signaling pathway 38
11.83 CXCL8 IL1B TNF
13
Hematopoietic cell lineage 38
11.82 IL1B ITGA3 TNF
14
Amoebiasis 38
11.81 CXCL8 IL10 IL1B TNF
15
Rheumatoid arthritis 38
11.78 CXCL8 IL1B TNF
16
Diseases of metabolism 67
Show member pathways
 11.73 SFTPA1 SFTPA2 SFTPB SFTPC SFTPD
17
Innate Lymphoid Cell Differentiation Pathways 66
11.72 IL10 IL1B TNF
18
Dendritic Cells Developmental Lineage Pathway 66
11.68 IL10 IL1B TNF
19